Celcuity's breast cancer win; Odyssey plans $205M IPO
Celcuity’s breast cancer drug wins again: The company said two regimens with its experimental drug gedatolisib succeeded in PIK3CA mutant patients as part of its Phase 3 trial. Last year ...
Original Source
Read the full article at Endpoints →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.